MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics announced preliminary survival data from its phase 1 study of agenT-797, an iNKT cell therapy for COVID-19 patients experiencing respiratory distress. The therapy achieved a 77% survival rate among older, ventilated patients, significantly higher than the national average of 20-30%. Additional findings showcased evidence of tumor biomarker suppression and disease stabilization beyond 6 months in relapsed/refractory multiple myeloma patients. The company plans to expand its clinical programs, including trials for solid tumors cleared by the FDA.
MiNK Therapeutics announced new data presentations at the 36th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing the potential of its iNKT cell therapies, particularly agenT-797. The data emphasize anti-tumor activity, tissue distribution, and the engineered iNKT cells' capabilities against solid and liquid tumors. Presentations will cover three abstracts, detailing clinical persistence and preclinical efficacy. The full text of the abstracts will be available on November 9, ahead of the investor section release on November 12.
MiNK Therapeutics has successfully closed its initial public offering of 3,333,334 shares of common stock at a price of $12.00 per share, generating gross proceeds of approximately $40 million. The shares began trading on the Nasdaq Global Market under the ticker symbol INKT on October 15, 2021. The offering was managed by Evercore ISI and William Blair, with co-managers B. Riley and Baird. This funding will support the company’s efforts to develop its pioneering iNKT cell therapies for cancer and immune-mediated diseases.
MiNK Therapeutics, a clinical stage biotechnology firm, announced its initial public offering (IPO) of 3,333,334 shares at $12.00 each, aiming for gross proceeds of approximately $40 million. Trading is set to begin on Nasdaq under the ticker symbol INKT on October 15, 2021, with the offering closing around October 19, 2021. The underwriters are granted an option to buy an additional 500,000 shares. The IPO proceeds will support the development of allogeneic iNKT therapies for cancer and immune-mediated diseases.
MiNK Therapeutics, a biopharmaceutical company focused on iNKT cell therapies for cancer and immune diseases, has announced the acceptance of three abstracts for the Society for Immunotherapy of Cancer’s 36th Annual Meeting, scheduled for November 10-14, 2021. The presentations will cover AgenT-797, including its persistence, tissue distribution, and anti-tumor activity. Abstracts will be released on November 9, 2021, with data also available on the investor section of their website post-presentation on November 12, 2021.